Symptom profiles between individuals with prior COVID-19 and those with other acute respiratory infections (ARIs).
Three months after delisting, NGM Bio is back with $122M for slimmed-down pipeline
Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS